Australian life sciences company (ASX:OPT) has reported negative outcomes from its pivotal Phase 3 clinical trial involving the combination of its sozinibercept with Bayer's EYLEA (aflibercept) for treating wet age-related macular degeneration. …
Australian eye therapy company now focused on survival after clinical trial result
March 25, 2025 Latest NewsAustralian Biotech
Latest Video
New Stories
-
When it comes to the PBS and Budgets, the best guide to the future is the past
March 26, 2025 - - Latest News -
Budget reveals wholesaling arrangements are a future focus
March 25, 2025 - - Latest News -
'Surely, we can all do better than the nonsense of the past few weeks'
March 25, 2025 - -
Former Speaker of the House appointed as official patron of Rare Cancers Australia
March 25, 2025 - - Latest News -
Another day, and another addition to what is now a motherload of bad ideas
March 25, 2025 - - Latest News -
Australian eye therapy company now focused on survival after clinical trial result
March 25, 2025 - - Latest News -
Mark Butler: Patients waiting too long and 'as the Health Minister, of course, I am sorry for that'
March 24, 2025 - - Latest News